Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpointsExpects two more Phase 3...
Epidemics
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents...
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey...
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
Accelerated fourth quarter sales growth to 7.6%, organic growth* of 14.3%Appointed Rob Claypoole as President and Chief Executive Officer, bringing...
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire worldExpanded...
HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance
Bill Rutherford to Retire and Mike Marks to Become CFONASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and...
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of...
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively -...
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to...
NanoViricides to Present at the Biotech Showcase in San Fransisco
SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing...
Jasper Therapeutics, Inc. Announces Reverse Stock Split
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Verde Bio Holdings Announces Entry Into Business Combination Agreement with SensaSure Technologies, Inc.
Transaction will provide Formation Minerals Inc., a wholly-owned subsidiary of SensaSure Technologies, Inc. (OTCQB: SSTC) the ability to be one...
Verde Bio Holdings Announces Entry Into Business Combination Agreement with SensaSure Technologies, Inc.
Transaction will provide Formation Minerals Inc., a wholly-owned subsidiary of SensaSure Technologies, Inc. (OTCQB: SSTC) the ability to be one...